Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477–491

PubMed  Google Scholar 

Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–1691

PubMed Central  Google Scholar 

Yoon JH, Choi SK. Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes. J Liver Cancer. 2023;23:300–315

PubMed  PubMed Central  Google Scholar 

European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236

Google Scholar 

Minami Y, Kudo M. Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need. Hepatobiliary Surg Nutr. 2019;8:414–416

PubMed  PubMed Central  Google Scholar 

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–207

PubMed  Google Scholar 

Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69:1284–1293

PubMed  Google Scholar 

Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594–604

CAS  PubMed  Google Scholar 

Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835–1847

CAS  PubMed  Google Scholar 

Lee D, Chung YH, Kim JA, Park WH, Jin YJ, Shim JH, et al. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer. 2013;119:2239–2246

CAS  PubMed  Google Scholar 

Yang S, Lin Q, Lin W, Hu W, Wang G. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World J Surg Oncol. 2016;14:159

PubMed  PubMed Central  Google Scholar 

Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28

PubMed  PubMed Central  Google Scholar 

Saung MT, Pelosof L, Casak S, Donoghue M, Lemery S, Yuan M, et al. FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist. 2021;26:797–806

CAS  PubMed  PubMed Central  Google Scholar 

Lin Z, Zhang X, Zhou Y, Chen C, He LN, Li H, et al. Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. Cancer Immunol Immunother. 2022;71:1247–1255

CAS  PubMed  Google Scholar 

Xu X, Yan S-L, Yo Y-T, Chiang P, Tsai C-Y, Lin L-L, et al. A Novel monoclonal antibody against PD-1 for the treatment of viral oncogene-induced tumors or other cancer. Cancers. 2024;16:3052

CAS  PubMed  PubMed Central  Google Scholar 

Qin A. Mechanism of action of ropeginterferon alfa-2b in polycythemia vera treatment. Clin Thera. 2024;46:439–440

CAS  Google Scholar 

Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023;13:1109866

CAS  PubMed  PubMed Central  Google Scholar 

Huang Y-W, Qin A, Tsai C-Y, Chen P-J. Novel pegylated interferon for the treatment of chronic viral hepatitis. Viruses. 2022;14:1128

CAS  PubMed  PubMed Central  Google Scholar 

Qin A, Wu CR, Ho MC, Tsai CY, Chen PJ. Sequential therapy with ropeginterferon alfa-2b and anti-programmed cell death 1 antibody for inhibiting the recurrence of hepatitis B-related hepatocellular carcinoma: From animal modeling to phase I clinical results. Int J Mol Sci. 2023;25:433s

Google Scholar 

Roche. Package Insert: PEGASYS®(Peginterferon alfa-2a); U.S. Food and Drug Administration: Silver Spring, MD, USA, 2002. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103964s5276lbl.pdf. Accessed 5 Sep 2024

Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708–720

PubMed  PubMed Central  Google Scholar 

Wong D, Littlejohn M, Edwards R, Jackson K, Revill P, Gaggar A, et al. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B. Liver Int. 2018;38:1760–1769

CAS  PubMed  Google Scholar 

Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis. 2013;56:100

CAS  PubMed  Google Scholar 

Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol. 2020;5:406–417

PubMed  PubMed Central  Google Scholar 

Qin A. An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Front Oncol. 2023;13:1173467

CAS  PubMed  PubMed Central  Google Scholar 

Qin A. A plain language summary about a cell cycle-based, new surveillance mechanism against cancer. Future Oncol. 2024;20(39):3209–3212

PubMed  PubMed Central  Google Scholar 

Qin X-Q, Beckham C, Brown JL, Lukashev M, Barsoum J. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther. 2001;4:356–364

CAS  PubMed  Google Scholar 

Brown JL, Barsoum J, Qin X-Q. CD4+ T helper cell-independent antitumor response mediated by murine IFN-β gene delivery in immunocompetent mice. J Interferon Cytokine Res. 2002;22:719–728

CAS  PubMed  Google Scholar 

Zhu Y, Chen M, Xu D, Li TE, Zhang Z, Li JH, et al. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma. Cell Mol Immunol. 2022;19:726–737

CAS  PubMed  PubMed Central  Google Scholar 

Hu B, Yu M, Ma X, Sun J, Liu C, Wang C, et al. IFNα potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov. 2022;12:1718–1741

CAS  PubMed  Google Scholar 

Huang YW, Hsu CW, Lu SN, Yu ML, Su CW, Su WW, et al. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatol Int. 2020;14:997–1008

PubMed  Google Scholar 

Lok AS-F. Hepatitis B treatment: what we know now and what remains to be researched. Hepatol Commun. 2019;3:8–19

Google Scholar 

Qin X-Q, Tao N, Dergay A, Moy P, Fawell S, Davis A, et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA. 1998;95:14411–14416

CAS  PubMed  PubMed Central  Google Scholar